Clinical Trial Update: Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating nitazoxanide for pre- and post-exposure prophylaxis of COVID-19 and other viral respiratory illnesses in at-risk individuals completed;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Viral Respiratory Infections

Drugs mentioned

• Nitazoxanide (nitazoxanide)

Snippet

Sponsor: Romark Laboratories L.C. | Conditions: COVID-19, Viral Respiratory Illnesses | Phase 3 | Status: COMPLETED | Results posted: 2024-06-26